1 INSERM UMR_S 999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis-Robinson, France.
2 Université Paris-Sud and Université Paris-Saclay, School of Médecine, Kremlin-Bicêtre, France.
Am J Respir Crit Care Med. 2015 Oct 15;192(8):983-97. doi: 10.1164/rccm.201402-0322OC.
Inflammation and endothelial dysfunction are considered two primary instigators of pulmonary arterial hypertension (PAH). CD74 is a receptor for the proinflammatory cytokine macrophage migration inhibitory factor (MIF). This ligand/receptor complex initiates survival pathways and cell proliferation, and it triggers the synthesis and secretion of major proinflammatory factors and cell adhesion molecules.
We hypothesized that the MIF/CD74 signaling pathway is overexpressed in idiopathic PAH (iPAH) and contributes to a proinflammatory endothelial cell (EC) phenotype.
Primary early passage cultures of human ECs isolated from lung tissues obtained from patients with iPAH and controls were examined for their ability to secrete proinflammatory mediators and bind inflammatory cells with or without modulation of the functional activities of the MIF/CD74 complex. In addition, we tested the efficacies of curative treatments with either the MIF antagonist ISO-1 or anti-CD74 neutralizing antibodies on the aberrant proinflammatory EC phenotype in vitro and in vivo and on the progression of monocrotaline-induced pulmonary hypertension.
In human lung tissues, intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin expressions are markedly up-regulated in the endothelium of distal iPAH pulmonary arteries. Circulating MIF levels are increased in the serum of patients with PAH compared with control subjects, and T-cell lymphocytes represent a source of this overabundance. In addition, CD74 is highly expressed in the endothelium of muscularized pulmonary arterioles and in cultured pulmonary ECs from iPAH, contributing to an exaggerated recruitment of peripheral blood mononuclear cells to pulmonary iPAH ECs. Finally, we found that curative treatments with the MIF antagonist ISO-1 or anti-CD74 neutralizing antibodies partially reversed development of pulmonary hypertension in rats and substantially reduced inflammatory cell infiltration.
We report here that CD74 and MIF are markedly increased and activated in patients with iPAH, contributing to the abnormal proinflammatory phenotype of pulmonary ECs in iPAH.
炎症和内皮功能障碍被认为是肺动脉高压(PAH)的两个主要诱因。CD74 是促炎细胞因子巨噬细胞移动抑制因子(MIF)的受体。该配体/受体复合物启动存活途径和细胞增殖,并触发主要促炎因子和细胞黏附分子的合成和分泌。
我们假设 MIF/CD74 信号通路在特发性 PAH(iPAH)中过度表达,并导致促炎的内皮细胞(EC)表型。
从 iPAH 患者和对照者的肺组织中分离出的人 EC 的早期传代培养物,检测其分泌促炎介质和与炎症细胞结合的能力,同时调节 MIF/CD74 复合物的功能活性。此外,我们还测试了 MIF 拮抗剂 ISO-1 或抗-CD74 中和抗体的治疗效果,观察其对体外和体内异常促炎 EC 表型以及单克隆鼠抗诱导的肺动脉高压进展的影响。
在人类肺组织中,细胞间黏附分子-1、血管细胞黏附分子-1 和 E-选择素在 iPAH 远端肺小动脉的内皮细胞中显著上调。与对照组相比,PAH 患者的血清中 MIF 水平升高,T 细胞淋巴细胞是这种过度表达的来源。此外,CD74 在肌性肺动脉小动脉的内皮细胞和 iPAH 的培养肺 EC 中高度表达,导致外周血单核细胞向肺 iPAH EC 的过度募集。最后,我们发现 MIF 拮抗剂 ISO-1 或抗-CD74 中和抗体的治疗可以部分逆转大鼠肺动脉高压的发展,并显著减少炎症细胞浸润。
我们在此报告,CD74 和 MIF 在 iPAH 患者中显著增加和激活,导致 iPAH 中肺 EC 的异常促炎表型。